Meloxicam injection (Anjeso) approved in US for management of moderate to severe pain alone or in combination with other non-NSAID analgesics

The approval for this once daily intravenous COX-2 preferential NSAID is supported by data from three Phase III studies showing reduced pain vs placebo in patients who underwent surgeries, including hip and knee replacements, abdominoplasty and bunionectomy.


Biospace Inc.